Sumitomo Pharma Co., Ltd.

4506

JP3495000006

Pharmaceuticals

Delayed Japan Exchange Other stock markets 07:00:00 17/05/2024 BST			5-day change	1st Jan Change
336 ^JPY	0.00%		-17.44%	-27.90%

05-09	Sumitomo Pharma Co., Ltd. agreed to acquire MELTz Business of MELTIN MMI Co., Ltd.	CI
05-07	Profit-Taking, China Outlooks Churn Asian Stock Markets	MT

Sumitomo Pharma Co., Ltd. Announces Executive Changes

July 10, 2023 at 12:30 pm

Sumitomo Pharma Co., Ltd. announced that Sumitomo Pharma America Inc. President and Chief Executive Officer, Myrtle Potter, Chief Executive Officer of Biopharma, Adele Gulfo, and Chief Medical Officer, Armin Szegedi, were appointed as Executive Officers of Sumitomo Pharma Co. Ltd. effective July 1, 2023.

Latest news about Sumitomo Pharma Co., Ltd.

Sumitomo Pharma Co., Ltd. agreed to acquire MELTz Business of MELTIN MMI Co., Ltd.	05-08	CI
Profit-Taking, China Outlooks Churn Asian Stock Markets	05-07	MT
Fed Outlook, Earnings Season Roil Asian Stock Markets	05-02	MT
Sumitomo Pharma Sees Impairment Losses and Restructuring Expenses in Fiscal 2024	05-02	MT
Sumitomo Pharma Expects Substantial Valuation Loss on Subsidiary Shares; Assures No Impact on Consolidated Profit	05-02	MT
Lull in Geopolitical Tensions Lifts Asian Stock Markets	04-22	MT
Jefferies Adjusts Sumitomo Pharma’s Price Target to 420 Yen From 520 Yen, Keeps at Hold	04-17	MT
Roivant Sciences Says Study of Potential Uveitis Treatment Meets Endpoints; Launches Stock Repurchase; Shares Rise	04-02	MT
Roivant's anti-inflammatory drug succeeds in mid-stage study	04-02	RE
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical	03-18	MT
Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from S&P Japan 500	03-17	CI
Sumitomo Pharma Enters into an Agreement to Amend the Worldwide Collaboration and License Agreement for Four Psychiatry and Neurology Compounds Including Ulotaront with Otsuka	03-15	CI
US Inflation Report Lifts Asian Stock Markets	03-01	MT
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses	02-16	MT
Japan's Nikkei slips after Fed chair signals delay in rate cut	02-01	RE
Transcript : Sumitomo Pharma Co., Ltd., Q3 2024 Earnings Call, Jan 31, 2024	01-31
Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024	01-31	CI
Sumitomo Pharma Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024	01-31	CI
Fed, China Property Outlooks Roil Asian Stock Markets	01-30	MT
Japan's Nikkei rounds off 2023 with biggest yearly gain in a decade	12-29	RE
Interest Rates, China Housing Measures Lift Asian Stock Markets	12-15	MT
China Real Estate, FX Roil Asian Stock Markets	11-29	MT
Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®	11-02	CI
European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis	11-02	CI
Japanese Shares End Higher on Tuesday After BOJ Kept Rate Unchanged; Shares of Nippon Electric Glass Jump Over 10%	31/10/23	MT

Chart Sumitomo Pharma Co., Ltd.

Duration

Period

More charts

Company Profile

Sumitomo Pharma Co., Ltd. (formerly Sumitomo Dainippon Pharma Co., Ltd.) specializes in development, manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows: - pharmaceuticals (92.9%): for cardiovascular, gastrointestinal and infectious diseases, central nervous systems disorders and allergies treatment; - other (7.1%): veterinary drugs, food additives, industrial chemical products, etc. Net sales are distributed geographically as follows: Japan (39.8%), the United States (50.4%), North America (0.9%) and other (8.9%).

Sector

Pharmaceuticals

Calendar

28/07/2024 - Q1 2024 Earnings Release (Projected)

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Sumitomo Pharma Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

UNDERPERFORM

Number of Analysts

Last Close Price

336 JPY

Average target price

333.8 JPY

Spread / Average Target

-0.67%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SUMITOMO PHARMA CO., LTD.	-27.90%	859M
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B

Other Pharmaceuticals